kinesin family member 5AGenealiases: ALS25 · D12S1889 · MY050 · NEIMY · NKHC · SPG10
Q-omics provides the consensus-scored KIF5A profile across patient tissues and cancer cell-line models. KIF5A expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, KIF5A is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, KIF5A RNA expression shows 18,503 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, and GBM as cancer lineages where KIF5A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KIF5A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KIF5A survival associations across molecular data types. KIF5A RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KIF5A RNA expression–survival associations across cancer types. High KIF5A expression shows unfavorable associations in KIRC, LIHC, KIRP and BLCA, but favorable associations in SKCM and PAAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for KIF5A RNA expression.
This table summarizes KIF5A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for KIF5A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KIF5A shows lower tumor expression in KIRC, KICH, KIRP, COAD and STAD and higher tumor expression in LUAD. The KIRC box plot shows higher KIF5A RNA expression in normal versus tumor tissue (log2 FC = −1.188, t-test p < 0.001).
This table shows molecular features associated with KIF5A in patient tissues and cancer cell lines. In patient samples, KIF5A shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, KIF5A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Lymphoma.
